Newtown, PA., May 12, 2025 (Globe Newswire) – Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or “Company”), a neurotech company focused on the supply of a new therapeutic risk, announced today a reimpage of balance and the reduction in the risk of major supplier.
“This additional approval and reimbursement of complaints from a second major health care provider at a typical price of the network validates more clinical needs and the advantages of the pons and strengthens the true value of the device. We believe that this award should support other constructive conversations with payers, “said Dane Andreff, President of Helius and Managing Director. “We continue to continue a commercial coverage of payers and a large reimbursement of third parties as part of our growth strategy aimed at increasing access to patients to the pons. We are satisfied with this progress in our efforts to support more patients with MS. ”
The total amount of reimbursement approved, including the co-payment of patients, was $ 18,100. This rate represents the approximated approximate list price for the state outside the network.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a main neurotech company in the field of medical devices focused on neurological deficits using an oral applied technological platform which amplifies the capacity of the brain to initiate physiological compensatory mechanisms and to promote neuroplasticity, improving the lives of people dealing with neurological diseases. The company’s first commercial product is the portable neuromodulation stimulator (PONS®). For more information on Pons or Helius Medical Technologies, visit www.heliusmedical.com.
About the Pons® and Therapy® device
The portable neuromodulation stimulator (“pons”) is an innovative, not implantable and applied oral therapy which provides neurostimulation by a mouthpiece connected to a controller while it is used, mainly at home, with a physical rehabilitation exercise, to improve balance and the approach. The PONS system, which provides light-language electric impulses, is indicated in the United States as short-term treatment of the march deficit due to the light to moderate to moderate plaques (“MS”) and should be used as a complement to a supervised therapeutic exercise program in 22-year-old and prescription patients.
Pons has shown its effectiveness in the treatment of the approach or balance and a significant reduction in the risk of falling in patients with stroke in Canada, where it has received an authorization to sell in three indications: (i) for use as a short -term treatment (14 weeks) of process deficit due to light and moderate stroke of stroke and must be used in conjunction with physiotherapy; (ii) for use as a short -term treatment (14 weeks) of chronic balance deficit due to a light to moderate (“mmtbi”) traumatic brain lesion and must be used in conjunction with physiotherapy; and (iii) for use as a short -term treatment (14 weeks) of a process deficit due to mild and moderate SEP symptoms and should be used in conjunction with physiotherapy. Pons is also authorized to sell in Australia for short -term use by health professionals in addition to a therapeutic exercise program to improve balance and the process. For more information, visit www.pontatherapy.com.
Declaration of non-responsibility for warning
Certain statements of this press release are not based on historical facts and constitute prospective declarations or prospective information within the meaning of the American law on the reform of private disputes of disputes and Canadian laws on securities. All declarations other than the historical facts included in this press release are prospective declarations that include risks and uncertainties. Prospective statements are often identified by terms such as “believing”, “wait”, “continue”, “will”, “objective”, “objective” and similar expressions. These prospective declarations include, among other things, declarations concerning the potential to expand the coverage of commercial payers and a large reimbursement of third parties within the framework of the growth strategy of the company aimed at increasing patient access to the pons.
There is no guarantee that such declarations will prove to be precise and that real results and future events could differ materially from those expressed or involved in such declarations. Important factors that could ensure that the real results differ considerably from the expectations of the company include uncertainties associated with the capital requirements of the company to achieve its commercial objectives, market conditions and the availability of third party funds to the manufacture of financing, the risks of the supply chain and the risks of the supply chain, in particular risks linked to the manufacture of dimber, the capacity of the company to obtain medical insurance Adequate and obtaining devices, the company’s ability to adapt medical insurance reimbursement code, the company’s ability to continue to build commercial infrastructure, secure state distribution licenses, market awareness of the pons fabric, future clinical trials and the clinical development processes, the product development processes and the FDA regulatory Submission Review and Approval Process, Other Development Activities, Ongoing Government Regulation, and other risks detailed from Time to Time in the “Risk Factors” Section of the Company’s Annual Report on Form 10-K for the Year Ended December 31, 2024, and its other deposits with the Securities and Exchange Commission of the United States and Canadian securities regulators, which can be obtained from www.sec.gov or www.sedar.com.
The reader is warned not to excessively release a prospective declaration. The prospective declarations contained in this press release are made on the date of this press release and the company assumes no obligation to update a prospective declaration or to update the reasons why the real results could delay these declarations, except to the extent required by law.
Contact on investors relations
Philip Trip Taylor
Gilmartin group
Investiture investigrique@heliusmedical.com
